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ABSTRACT
Peptidases (proteolytic enzymes or proteases), their
substrates and inhibitors are of great relevance to
biology, medicine and biotechnology. The MEROPS
database (http://merops.sanger.ac.uk) aims to fulfil
the need for an integrated source of information
about these. The organizational principle of the
database is a hierarchical classification in which
homologous sets of peptidases and protein inhibi-
tors are grouped into protein species, which are
grouped into families and in turn grouped into clans.
Important additions to the database include newly
written, concise text annotations for peptidase
clans and the small molecule inhibitors that are
outside the scope of the standard classification;
displays to show peptidase specificity compiled
from our collection of known substrate cleav-
ages; tables of peptidase–inhibitor interactions;
and dynamically generated alignments of repre-
sentatives of each protein species at the family
level. New ways to compare peptidase and inhibitor
complements between any two organisms whose
genomes have been completely sequenced, or
between different strains or subspecies of the
same organism, have been devised.
INTRODUCTION
The MEROPS database is a manually curated informa-
tion resource for peptidases (also known as proteases,
proteinases or proteolytic enzymes), their inhibitors and
substrates. The database has been in existence since 1996
and can be found at http://merops.sanger.ac.uk. Releases
are made quarterly.
Peptidases and protein inhibitors are arranged in
the database according to a hierarchical classiﬁcation.
The classiﬁcation is based on sequence comparisons of the
domains known to be important for activity (known as the
peptidase or inhibitor unit). A protein that has been
sequenced and characterized biochemically is chosen as
a representative (‘holotype’). All sequences that represent
species variants of the holotype are grouped into
a ‘protein species’. The sequences of statistically signiﬁcant
related protein species are grouped into a ‘family’. Families
that are believed to have had a common ancestor, either
because the tertiary structures of the proteins are similar or
(in the case of peptidases) active site residues are in the
same order in the sequence, are grouped into a ‘clan’ (1,2).
Statistics from release 7.8 (April 2007) of MEROPS are
shown in Table 1 and compared with release 7.1 from July
2005. The number of peptidase sequences has more than
doubled, whereas the numbers of protein families and
clans has increased only marginally. This reﬂects the
considerable eﬀort being put into completing genome
sequences. There has also been a signiﬁcant increase
(17%) in the number of peptidase species.
CLAN SUMMARIES
We have expanded the text summaries to include clans of
peptidases. A peptidase clan summary is structured under
the headings: description, history (when and where the clan
identiﬁer was ﬁrst published), contents of clan (a descrip-
tion of the types of peptidases contained within the clan),
evidence(anexplanationastowhythefamiliesareincluded
in the same clan), catalytic mechanism, peptidase activity,
protein fold (descriptions of the known tertiary structures
for members of the clan and to which families they belong),
homologous non-peptidase families (families of proteins
other than peptidases that share a similar tertiary
structure), evolution (pointing out possible relationships
that may exist with peptidases in other clans or signiﬁcant
absences amongst organism kingdoms), activation mecha-
nism and other databases (links to clans in the Pfam
database (3) and superfamilies in the SCOP database (4)).
SUBSTRATE DISPLAYS
Specificity logos
One of the most important characteristics of a peptidase
that distinguishes it from related peptidases is its action on
substrates. For some peptidases, such as trypsin, the
speciﬁcity is easily described because catalytic activity
action is restricted to cleavage of lysyl or arginyl bonds.
However, for many peptidases speciﬁcity is much more
complex, and is diﬃcult to deﬁne.
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tion that helps with the description of peptidase speciﬁcity.
The peptide chain around the cleavage site of the substrate
is assumed to thread through the active site of the
peptidase so that each binding pocket of the peptidase is
occupied by one amino acid, and many crystal structures
of peptidase–inhibitor complexes tend to conﬁrm this
model. The residues of the substrate C-terminal to the site
of cleavage (the ‘scissile bond’) are numbered P10,P 2 0,P 3 0,
etc. (the ‘prime side’), whereas those N-terminal to the
scissile bond are numbered P1, P2, P3, etc. (the ‘non-prime
side’). Each binding pocket of the peptidase (which may be
lined with several amino acid side chains) on the prime
side is numbered S10,S 2 0,S 3 0, etc. and those on the non-
prime side are numbered S1, S2, S3, etc. The number of
important binding pockets (and therefore substrate
residues) diﬀers between peptidases. In trypsin, speciﬁcity
is determined only by residues in P1 and P10 (only arginine
or lysine are acceptable in P1 and proline is not acceptable
in P10). Peptidases that have a speciﬁcity requirement
beyond P1 or P10 are said to have an ‘extended binding
site’. Mitochondrial intermediate peptidase, which
removes an N-terminal octapeptide targeting signal from
proteins destined for the mitochondrial lumen, may have
the longest extended binding site (6), but for most
peptidases binding rarely exceeds P4.
The MEROPS collection of cleavages in natural and
synthetic substrates now exceeds 7000. For each cleavage
we store up to four residues on either side of the scissile
bond (residues P4–P40). For any peptidase with more than
ten known cleavages we now present a display that gives an
indication of the amino acids preferred at its substrate-
binding sites. This display uses the WebLogo software (7).
For the purposes of this display, the eight residues P4–P40
for all substrates of a peptidase are considered to be an
alignment. The observed frequency of amino acids at each
position is calculated as a bit score, with the maximum
possible score being 4.32bits. At each position, the single-
lettercodeofanamino acidisshownifthebitscoreexceeds
0.1, and the height of the letter is proportional to the bit
score. Acidic residues are shown in red, basic in blue,
hydrophobic residues in black and others in green. Figure 1
shows the cleavage site sequence logo for caspase-3. The
logo shows an absolute requirement for aspartate in P1
(position 4) and a preference for aspartate in P4, and this
speciﬁcity has been conﬁrmed by experimentation (8).
In addition to the logo, a text string describing the
speciﬁcity is also shown (Figure 1). Where only one amino
acid predominates at a position, it is shown in uppercase if
the bit score exceeds 0.4. Where more than one amino acid
exceeds 0.1bits for a single position, a letter is shown in
uppercase if the bit score exceeds 0.7.
SMALL MOLECULE INHIBITORS
The MEROPS database has included protein inhibitors of
peptidases since 2004. However, there are many other
inhibitors that are not proteins, including peptides and
synthetic inhibitors, which we term small molecule
inhibitors (SMIs). These include many that are laboratory
reagents used in the characterization of peptidases, and
others that are drugs such as the inhibitors of the
retropepsin of the HIV virus. Information about SMIs
has now been collated and is presented within MEROPS.
There is no satisfactory, single method to classify SMIs, so
their names and alternative names are simply listed
alphabetically. For many SMIs summaries have been
written. Each summary contains a recommended name,
other names including the chemical name, history, details
of peptidases inhibited, a description of the mechanism of
Figure 1. Cleavage site sequence logo showing speciﬁcity for caspase-3. Amino acids preferred in positions P4–P40 are shown in single-letter code.
The speciﬁcity is shown as a string where each position is separated by a forward slash character and multiple letters in a position indicate a wide
speciﬁcity for these amino acids. The scissile bond is shown by a red cross symbol. In the diagram, the height of the letter is proportional to the
number of cleavage sites in which it is present. Positions P4–P40 are numbered one to eight, with the scissile bond between residues four and ﬁve.
Caspase-3, like most caspases, has a preference for Asp in P1 and a majority of substrates also have Asp in P4.
Table 1. Counts of protein species, families and clans for peptidase and
protein inhibitor homologues in the MEROPS database
MEROPS 7.8 MEROPS 7.1
Peptidases Inhibitors Peptidases Inhibitors
Sequences 66524 4912 30090 3690
Protein species 2403 571 2053 532
Families 185 53 180 53
Clans 51 33 39 32
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reference to the PubChem database (9), comments and
recommended reviews. An example summary page for
pepstatin is shown in Figure 2. In addition, a ‘Relevant
Inhibitors’ ﬁeld has been added to the peptidase summa-
ries, which lists SMIs that are known to inhibit the
peptidase or that do not inhibit even if expected to. Each
item in the list has a link to the relevant SMI summary.
INHIBITOR DISPLAYS
We have collected over 900 known peptidase–protein
inhibitor interactions from the literature. At least one
interaction with a peptidase is known for 375 inhibitor
species. We now present a table of interactions for each
inhibitor, which includes a link to relevant peptidase
summary, a reference and some details such as a published
Ki (dissociation constant) ﬁgure and conditions or
comments about the interaction. An example is shown
in Figure 3. A similar table is also presented for each
peptidase, listing the inhibitors with which it interacts.
COMPARATIVE GENOMICS
Comparison ofpeptidase/inhibitor complement between
strains ofan organism
It is commonplace for several strains of a bacterium to be
subjected to genome sequencing. In MEROPS, we have
always maintained a non-redundant sequence collection,
and only one variant of a protein sequence is retained,
unless there is evidence that the proteins are products of
diﬀerent genes. This has meant that for each bacterial
protein we display only one sequence, even though
variations may be known from several diﬀerent strains.
All proteins derived from the same species have been
considered part of the same genomic complement,
regardless of strain. This approach may hide unique
expression of proteins that may have medical signiﬁcance.
For example, not all strains of Escherichia coli are
pathogenic, and peptidases or inhibitors restricted to
pathogenic strains may be of medical importance.
Similarly, some proteins important for pathogenicity
may be inactivated by residue replacements in non-
pathogenic strains. To address this problem, whilst still
maintaining our non-redundant sequence collection, we
have made use of our nucleotide database sequence
accession collection, which is now annotated below the
species level (subspecies, strain, pathovar, etc.).
We now present two displays showing comparison of
peptidases or inhibitors between strains of a prokaryote
organism. The user is invited to select an organism from a
list of prokaryotes with completed genomes. The ﬁrst
display shows clans and families and the number of
sequences in each family for each strain. This enables the
user to spot absences or additional members for the strain
of interest. The second display is at the protein species
level. Not only can absences or additional proteins be
observed, but also we provide a dynamically generated
alignment so that conservation of residues for the same
Figure 2. Example SMI page. The summary page for the inhibitor pepstatin is shown.
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sequences are taken directly from the UniProt protein
sequence database (10) and the alignment is generated by
the MUSCLE software package (11).
To complement these changes, the genomes pages now
show counts of peptidases and protein inhibitors at the
strain level.
Comparison of peptidase/inhibitor complements
between organisms
We have also developed a display so that comparisons can
be made between any two organisms with completely
sequenced genomes, not just prokaryotes. The comparison
can be done at the family or protein species levels, and
counts are shown of peptidase homologues for each
species. Signiﬁcant diﬀerences between the organisms are
highlighted. At the family level, separate counts are shown
for homologues presumed to be peptidases (i.e. possessing
all active site residues) and those that are predicted to be
non-peptidase homologues (with an unacceptable replace-
ment of at least one active site residue). Figure 4 shows
part of the comparison between human and the patho-
genic fungus Candida albicans (the causative agent of
thrush) at the family level. The only peptidase family
present in C. albicans but absent in humans is S64, which
includes the Ssy5 peptidase, a component of the pathways
for the uptake of external amino acids; the peptidase
activates the Stp1 transcription factor leading to
production of an amino acid permease (12). This identiﬁes
the Ssy5 peptidase as a potential drug target, because
no homologue exists in human and the equivalent
gene has been shown to be essential in Saccharomyces
cerevisiae by the Saccharomyces Genome Deletion
Project (13).
ALIGNMENTS AND TREES
Dynamic alignments for holotypes
With the completion of so many prokaryote and
eukaryote genomes, the number of sequences within
some families now exceeds a thousand. The alignments
we generate can therefore be very large. However, within
any family the number of proteins characterized well
enough to be considered holotypes is still small. The
family with most holotypes is S1, for which there are
over 3000 sequences and 400 holotypes. So that the
variability within a family can be more easily understood,
we now generate an alignment of peptidase or inhibitor
units just for the holotypes in each family. The MUSCLE
software package (11) is used to generate each alignment.
Active site residues, disulphide bridges, carbohydrate-
attachment sites and transmembrane regions are
highlighted.
Newlabel keys forfamily alignments andtrees
The label keys for the family alignments and trees are now
generated dynamically. The content of each line has been
altered and now shows the MEROPS identiﬁer (linked to
the relevant summary page), the organism name (linked to
the relevant organism card), the recommended name
(and any subset of that name), the MEROPS accession
number for the sequence (linked to the sequence page),
and the extent of the peptidase or inhibitor unit.
SUMMARY
The focus of the MEROPS database for the last 2 years
has been towards the addition of further annotation at the
protein species level. One peptidase species can be
distinguished from another by several criteria, including
Figure 3. Peptidase–inhibitor interactions for aprotinin.
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include displays for both of these aspects. New tools
enable the user compare peptidases and protein inhibitor
species between strains of the same organism or between
organisms.
AVAILABILITY
The database is freely available and can be accessed from
http://merops.sanger.ac.uk. Our sequence databases in
FastA format and versions of the database as either ﬂat
ﬁles or a compressed ﬁle of SQL statements for import
into MySQL can be uploaded from our FTP site (ftp://
ftp.sanger.ac.uk/pub/MEROPS).
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